Initial salt screening procedures for manufacturing ibuprofen

Drug Development and Industrial Pharmacy

Volumn 35, Issue 5, 2009, Pages 555-567

  Lee, Tu ^a   Wang, Yeh Wen ^a  

^a NATIONAL CENTRAL UNIVERSITY   (Taiwan)

Author keywords

Ibuprofen; Initial salt screening; Sodium ibuprofen dihydrate; Tris(hydroxymethyl)aminomethane; Trizma base

Indexed keywords

2 PROPANOL; ACETONE; ACETONITRILE; ALCOHOL; AMINE; ARGININE; DIETHANOLAMINE; DIMETHYL SULFOXIDE; DIOXANE; HISTIDINE; IBUPROFEN; IBUPROFEN DERIVATIVE; LYSINE; METHANOL; N,N DIMETHYLFORMAMIDE; ORGANIC SOLVENT; POTASSIUM HYDROXIDE; SODIUM CHLORIDE; SODIUM HYDROXIDE; SODIUM IBUPROFEN DIHYDRATE; TETRAHYDROFURAN; TROMETAMOL; UNCLASSIFIED DRUG; WATER; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; INORGANIC SALT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ATMOSPHERE; CRYSTAL STRUCTURE; DISSOLUTION; DRUG DESIGN; DRUG MANUFACTURE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FLOW KINETICS; HYDROPHOBICITY; MELTING POINT; MOLECULAR WEIGHT; RACEMIZATION; SCINTILLATION; SUSTAINED DRUG RELEASE; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONTAMINATION; DRUG INDUSTRY; HUMIDITY; INFRARED SPECTROSCOPY; KINETICS; PH; SOLUBILITY; SOLUTION AND SOLUBILITY; STEREOISOMERISM; THERMOGRAVIMETRY; X RAY DIFFRACTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG CONTAMINATION; DRUG INDUSTRY; HUMIDITY; HYDROGEN-ION CONCENTRATION; IBUPROFEN; INDICATORS AND REAGENTS; KINETICS; MODELS, MOLECULAR; SALTS; SOLUBILITY; SOLUTIONS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STEREOISOMERISM; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 67049109670     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802459452     Document Type: Article

References (57)

1. Agharkar, S., Lindenbaum, S., & Higuchi, T. (1976). Enhancement of solubility of drug salts by hydrophilic counterions: Properties of organic salts of an antimalarial drug. J. Pharm. Sci., 65(5), 747-749.
2. Alsenz, J., & Kansy, M. (2007). High throughput solubility measurement in drug discovery and development. Adv. Drug Deliv. Rev., 59(7), 546-567.
3. Armitage, B. J., Lampard, J. F., & Smith, A. (2001). Composition of S(-) sodium ibuprofen. US Patent No. 6,242,000 B1.
4. Balbach, S., & Korn, C. (2004). Pharmaceutical evaluation of early development candidates "the 100 mg-approach." Int. J. Pharm., 275(1-2), 1-12.
5. Barton, A. F. M. (1991). Solvent scales. In CRC handbook of solubility parameters and other cohesion parameters. (2nd ed., chap. 8, pp. 294-295). Boston, USA: CRC Press.
6. Bastin, R. J., Bowker, M. J., & Slater, B. J. (2000). Salt selection and optimisation procedures for pharmaceutical new chemical entities. Org. Proc. Res. Dev., 4(5), 427-435.
7. Berge, S. M., Bighley, L. D., & Monkhouse, D. C. (1977). Pharmaceutical salts. J. Pharm. Sci., 66(1), 1-19.
8. Black, S. N., Collier, E. A., Davey, R. J., & Roberts, R. J. (2007). Structure, solubility, screening, and synthesis of molecular salts. J. Pharm. Sci., 96(5), 1053-1068.
9. Bruzzese, T., Ferrari, R., & SPA-Socita Prodotti Antibiotici. (1981). Method of relieving pain and treating inflammatory conditions in warm-blooded animals. US Patent No, 4279926.
10. Bunyan, J. M. E., Shankland, N., & Sheen, D. B. (1991). Solvent effects on the morphology of ibuprofen. AIChE Symp. Ser., 87(284), 44-57.
11. Cano, H., Gabas, N., & Canselier, J. P. (2001). Experimental study on the ibuprofen crystal growth morphology in solution. J. Cryst. Growth, 224(3-4), 335-341.
12. Carlson, E. D., Cong, P., Chandler, W. H., Jr., Desrosiers, P. J., Christopher Freitag, J., & Varni, J. F., & Symyx Technologies. (2005). Apparatuses and methods for creating and testing pre-formulations and systems for same. US Patent No. 6,939,515 B2.
13. Chidambaram, R., Derbin, G. M., Endo, M., Gao, J., Lee, T., Motheram, R., Parker, W. L., Rosso, V. W., Varia, S. A., & Bristol-Myers Squibb. (2007). Oral Administration of N-(2-Chloro-6-Methylphenyl)-2-[[6-[4-(2-Hydroxyethyl)- 1-Piper-Azinyl]-2-Methyl-4-Pyrimidinyl]Amino]-1,3-Thiazole-5- Carboxamide and Salts Thereof, WO 035874, A1.
14. Colthup, N. B., Daly, L. H., & Wiberley, S. E. (1990a). Amines, C=N, and N=O compounds. In Introduction to infrared and Raman spectroscopy. (3rd ed., chap. 11, pp. 340-343). San Diego, CA: Alexander Press.
15. Colthup, N. B., Daly, L. H., & Wiberley, S. E. (1990b). Carbonyl compounds. In Introduction to infrared and Raman spectroscopy. (3rd ed., chap. 9, pp. 317-319). San Diego, CA: Alexander Press.
16. Constable, D. J. C., Jimenez-Gonzalez, C., & Henderson, R. K. (2007). Perspective on solvent use in the pharmaceutical industry. Org. Proc. Res. Dev., 11(1), 133-137.
17. Eilerman, D., & Rudman, R. (1980). Polymorphism of crystalline poly(hydroxymethyl) compounds. III. The structures of crystalline and plastic tris(hydroxymethyl)aminomethane. J. Chem. Phys., 72(10), 5656-5666.
18. Engel, G. L., Farid, N. A., Faul, M. M., Richardson, L. A., & Winneroski, L. L. (2000). Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm., 198(2), 239-247.
19. Fleischman, S. G., Kuduva, S. S., McMahon, J. A., Moulton, B., Bailey Walsh, R. D., Rodríguez-Hornedo, N., & Zaworotko, M. J. (2003). Crystal engineering of the composition of pharmaceutical phases: Multiple-component crystalline solids involving carbamazepine. Cryst. Growth Des. 3(6), 909-919.
20. Freer, A. A., Bunyan, J. M., Shankland, N., & Sheen, D. B. (1993). Structure of (S)-(+)-ibuprofen. Acta Cryst., C49, 1378-1380.
21. Garzón, L. C., & Martínez, F. (2004). Temperature dependence of solubility for ibuprofen in some organic and aqueous solvents. J. Sol. Chem., 33(11), 1379-1395.
22. Gould, P. L. (1986). Salt selection for basic drugs. Int. J. Pharm., 33(1-3), 201-217.
23. Gwak, H.-S., Choi, J.-S., & Choi, H.-K. (2005). Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int. J. Pharm., 297(1-2), 156-161.
24. Hansen, L. Kr., Perlovich, G. L., & Bauer-Brandl, A. (2003). Redetermination and H-atom refinement of (S)-(+)-ibuprofen. Acta Cryst., E59(9), o1357-o1358.
25. Hehm, S. J., Rodríguez-Spong, B., & Rodríguez-Hornedo, N. (2006). Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst. Growth Des., 6(2), 592-600.
26. Jones, H. P., Davey, R. J., & Cox, B. G. (2005). Crystallization of a salt of a weak organic acid and base: Solubility relations, supersaturation control and polymorphic behavior. J. Phys. Chem. B, 109(11), 5273-5278.
27. Kawakami, K., Ida, Y., & Yamaguchi, T. (2005). Effect of salt type on hygroscopicity of a new cephalosporin S-3578. Pharm. Res., 22(8), 1365-1373.
28. Khan, G. M., & Jiabi, Z. (1998). Preparation, characterization, and evaluation of physicochemical properties of different crystalline forms of ibuprofen. Drug Dev. Ind. Pharm., 24(5), 463-471.
29. Kim, S., Wei, C., & Kiang, S. (2003). Crystallization process development of an active pharmaceutical ingredient and particle engineering via the use of ultrasonics and temperature cycling. Org. Proc. Res. Dev., 7(6), 997-1001.
30. Klenell, M., Snoeijs, P., & Pedersén, M. (2004). Active carbon uptake in Laminaria digitata and L. saccharina (Phaeophyta) is driven by a proton pump in the plasma membrane. Hydrobiologia, 514(1-3), 41-53.
31. Kumar, L., Amin, A., & Bansal, A. K. (2007). An overview of automated systems relevant in pharmaceutical salt screening. Drug Discov. Today, 12(23-24), 1046-1053.
32. Lee, T., Chen, Y. H., & Wang, Y. W. (2008). Effects of homochiral molecules of (S)-(+)-ibuprofen and (S)-(?)-sodium ibuprofen dihydrate on the crystallization kinetics of racemic (R,S)-(±)-sodium ibuprofen dehydrate. Cryst Growth Des., 8(2), 415-426.
33. Lee, T., Chen, Y. H., & Zhang, C. W. (2007). Solubility, polymorphism, crystallinity, crystal habit, and drying scheme of (R,S)-(?)-sodium ibuprofen dihydrate. Pharm. Tech., 31(6), 72-87.
34. Lee, T., Kuo, C. S., & Chen, Y. H. (2006). Solubility, polymorphism, crystallinity, and crystal habit of acetaminophen and ibuprofen by initial solvent screening. Pharm. Tech., 30(10), 72-92.
35. Li, S., Wong, S., Sethia, S., Almoazen, H., Joshi, Y. M., & Serajuddin, A. T. M. (2005). Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm. Res., 22(4), 628-635.
36. Lide, D. R. (2005). Biochemistry. In CRC handbook of chemistry and physics (86th ed., sect. 7, p. 7-1). Boston, MA: CRC Press.
37. Martino, P. D., Beccerica, M., Joiris, E., Palmieri, G. F., Gayot, A., & Martelli, S. (2002). Influence of crystal habit on the compression and the densification mechanism of ibuprofen. J. Cryst. Growth, 243(2), 345-355.
38. Morissette, S. L., Almarsson, Ö., Paterson, M. L., Remenar, J. F., Read, M. J., Lemmo, A. V., Ellis, S., Cima, M. J., & Gardner, C. R. (2004). Highthroughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug Deliv. Rev., 56(3), 275-300.
39. Morris, K. R., Fakes, M. G., Thakur, A. B., Newman, A. W., Singh, A. K., Venit, J. J., & Spagnuolo, C. J., Serajuddin, A. T. M. (1994). An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm., 105(3), 209-217.
40. Nada, A. H., Al-Saidan, S. M., & Mueller, B. W. (2005). Improving the physical and chemical properties of ibuprofen. Pharm. Tech., 29(11), 90-101.
41. Oberoi, L. M., Alexander, K. S., & Riga, A. T. (2005). Study of interaction between ibuprofen and nicotinamide using differential scanning calorimetry, spectroscopy, and microscopy and formulation of a fast-acting and possibly better ibuprofen suspension for osteoarthritis patients. J. Pharm. Sci., 94(1), 93-101.
42. Perlovich, G. L., Kurkov, S. V., Hansen, L. K., & Bauer-Brandl, A. (2004). Thermodynamics of sublimation, crystal lattice energies, and crystal structures of racemates and enantiomers: (+)- And (?)-ibuprofen. J. Pharm. Sci., 93(3), 654-666.
43. Rasenack, N., & Müller, B. W. (2002). Properties of ibuprofen crystallized under various conditions: A comparative study. Drug Dev. Ind. Pharm., 28(9), 1077-1089.
44. Remenar, J. F., Morissette, S. L., Peterson, M. L., Moulton, B., Michael MacPhee, J., Guzmán, H. R., & Almarson, Ö. (2003). Crsytal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J. Am. Chem. Soc., 125(28), 8456-8458.
45. Rodríguez-Hornedo, N., & Murphy, D. (2004). Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J. Pharm. Sci., 93(2), 449-460.
46. Romero, A. J., & Rhodes, C. T. (1991). Approaches to stereospecific preformulation of ibuprofen. Drug Dev. Ind. Pharm., 17(5), 777-792.
47. Romero, A. J., Savastano, L., & Rhodes, C. T. (1993). Monitoring crystal modifications in systems containing ibuprofen. Int. J. Pharm., 99(2-3), 125-134.
48. Sádaba, B., Campanero, M. A., Muñoz-JuarezGil-Aldea, M. J., García- Quetglas, I., Esteras, E. A., & Azanza, J. R. (2006). A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers. Eur. J. Clin. Pharmacol., 62(10), 849-854.
49. Serajuddin, A. T. M. (2007). Salt formation to improve drug solubility. Adv. Drug Deliv. Rev., 59(7), 603-616.
50. Shankland, K., David, W. I. F., Csoka, T., & McBride, L. (1998). Structure solution of ibuprofen from powder diffraction data by the application of a generic algorithm combined with prior conformational analysis. Int. J. Pharm., 165(1), 117-126.
51. Shankland, N., Wilson, C. C., Florence, A. J., & Cox, P. J. (1997). Refinement of ibuprofen at 100 k by single-crystal pulsed neutron diffraction. Acta Cryst., C53, 951-954.
52. Sorasuchart, W., Wardrop, J., & Ayres, J. W. (1999). Drug release from spray layered and coated drug-containing beads: Effects of pH and comparison of different dissolution methods. Drug Dev. Ind. Pharm., 25(10), 1093-1098.
53. Steffen Paulekuhn, G., Dressman, J. B., & Saal, C. (2007). Trends in active pharmaceutical ingredient salt selection based on analysis of the orange book database. J. Med. Chem, 50(26), 6665-6672.
54. Terashima, K., Kageyama, S., Katsuyama, H., & Fuji Photo Film Co., Ltd. (1990). Integral multilayer analytical element for use in the measurement of alkaline phosphatase activity. US Patent No. 4,900,665.
55. Trask, A. V., Haynes, D. A., Samual Motherwell, W. D., & Jones, W. (2006). Screening for crystalline salts via mechanochemistry. Chem. Commun., 51-53.
56. Winn, D., & Doherty, M. F. (1998). A new technique for predicting the shape of solution-grown organic crystals. AIChE J., 44(11), 2501-2514.
57. Zhang, Y., & Grant, D. J. W. (2005). Similarity in structures of racemic and enantiomeric ibuprofen sodium dihydrates. Acta Cryst., C61, m435-m438.